Medicine Industry's Gateway to NICE
The Innovation Observatory is the gateway to the NICE Technology Assessment (TA) Programme for industry, preventing delays in bringing new and repurposed medicines to the UK market through the early identification and tracking of new and repurposed medicines and health technologies.
The National Institute for Health and Care Excellence (NICE) TA programme provides UK healthcare guidance through Technology Appraisals and Highly Specialised Technologies assessments. A NICE recommendation is crucial for market access to the NHS in England and Wales. The Innovation Observatory is the first step in the process and we work closely with our pharmaceutical industry partners.
We provide the 'gateway' to NICE by submitting potential topics that meet the NICE Topic Selection criteria for medicines as set out in the NICE Topic Selection Manual. We follow the development of new and repurposed medicines from at least two years before estimated UK licence to provide a timely notification to NICE. This early notification triggers the NICE TA process and allows NICE to provide new guidelines as close to the licence date as possible.
The Innovation Observatory has a strict confidentiality agreement which means we only share confidential information with selected policymakers.
Atezolizumab with platinum-based chemotherapy and bevacizumab for epithelial ovarian cancer or fallopian tube cancer or primary peritoneal cancer
Atezolizumab in combination with bevacizumab and chemotherapy is currently in clinicaldevelopment for the treatment of patients with epithelial ovarian cancer or primary peritonealor fallopian tube cancer. Epithelial ovarian cancers are the most common type of ovarian cancer.Primary peritoneal cancer and fallopian tube cancer are similar to epithelial ovarian cancer. Allthree types show signs of pain […]
DownloadTirzepatide for treating obese or overweight adults
Tirzepatide is in clinical development for the treatment of obesity or overweight individuals with weight-related comorbidities (e.g., sleep apnoea, cardiovascular disease). Excess weight can place stress on both mental and physical health, leading to complications such as depression, low self-esteem, and increased risk of heart disease, stroke, and type 2 diabetes. Weight can be affected […]
DownloadHigh-dose aflibercept for diabetic macular oedema
High-dose aflibercept is in clinical development for the treatment of diabetic macular oedema. DMO is swelling of the macula caused by diabetes or by blockage of the veins behind the retina and it is the most common cause of sight loss in people with diabetes. DMO occurs when blood vessels damaged by high blood sugar […]
DownloadHigh dose aflibercept for treating neovascular age-related macular degeneration (nAMD)
High dose aflibercept is in development for the treatment of neovascular age-related macular degeneration (nAMD). nAMD is a condition that commonly affects people over the age of 50 and causes vision disturbance or blind spots in the centre of the visual field and progresses rapidly over several weeks or months without any treatment. Aflibercept is […]
DownloadNivolumab adjuvant for treating for stage IIB/IIC resected melanoma
Nivolumab is in clinical development as a therapy to be given to patients who have had stage IIB-IIC melanoma removed via surgery but who are at high risk of recurrence. Melanoma is a type of skin cancer that is commonly caused by sun exposure and is often first noticed as a new mole or a […]
DownloadIptacopan for paroxysmal nocturnal haemoglobinuria
Iptacopan is in development for the treatment of paroxysmal nocturnal haemoglobinuria (PNH). PNH is a rare condition, which occurs due to a genetic change within cells in the bone marrow. In PNH, blood cells lack specific proteins on their surface which normally protect them from being destroyed (a process called haemolysis in red blood cells) […]
DownloadPembrolizumab perioperative therapy with neoadjuvant chemotherapy for treating cisplatin eligible muscle-invasive bladder cancer
Pembrolizumab perioperative (preoperative and postoperative) therapy in combination with neoadjuvant (before surgery) chemotherapy is in development for the treatment of patients with cisplatin eligible muscle invasive bladder cancer (MIBC). MIBC is when the cancer has spread beyond the lining of the bladder and into the muscle layer. The most well-known risk factor for MIBC is […]
DownloadLinzagolix choline for treating moderate to severe symptoms associated with uterine fibroids in adult women of reproductive age
Linzagolix choline is currently in clinical development for the treatment of moderate to severe symptoms of uterine fibroids (UFs) in adult women. UFs are the most common form of benign uterine tumours, causing heavy menstrual bleeding, pelvic pain, infertility, and pressure symptoms. They can also cause bleeding between periods, anaemia, abdominal pain and cramping, painful […]
DownloadApadamtase alfa for treating acute thrombotic thrombocytopenic purpura (TTP) episodes associated with congenital TTP (cTTP) and long-term prophylaxis in patients with congenital ADAMTS-13 deficiency
Apadamtase alfa is currently in clinical development for treating thrombotic thrombocytopenic purpura (TTP) episodes associated with congenital TTP (cTTP) and long-term prophylaxis in patients with congenital ADAMTS-13 deficiency. Congenital ADAMTS-13 occurs when genetic mutations lead to low levels of the ADAMTS-13 enzyme (a protein). This condition is characterised by recurrent episodes of acute (sudden onset) […]
DownloadAtezolizumab with cabozantinib for advanced renal cell carcinoma after 1 therapy
Atezolizumab in combination with cabozantinib is in clinical development for the treatment of advanced renal cell carcinoma (RCC) after prior treatment. RCC (also called kidney cancer) is a disease that affects the lining of tiny tubes within the kidney which filter waste from the blood, making urine. In many cases of RCC there are no […]
DownloadNivolumab-ipilimumab for previously untreated advanced hepatocellular carcinoma
Nivolumab and ipilimumab is in development for the first-line treatment of advanced hepatocellular carcinoma (HCC). HCC is the most common type of primary liver cancer, which affects men more than women, and is more likely to develop the older a person gets. Advanced HCC means the cancer is incurable. Symptoms include weight loss, jaundice (yellowing […]
DownloadOtilimab in combination with conventional synthetic DMARDs for treating rheumatoid arthritis
Otilimab in combination with conventional synthetic disease-modifying antirheumatic drugs (DMARDs) is in clinical development for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA), who have had an inadequate response to conventional synthetic DMARDs and/or targeted therapies (biologic DMARDs and Janus Kinase inhibitors). RA is a chronic autoimmune condition where the […]
DownloadDurvalumab with gemcitabine-cisplatin neoadjuvant treatment and durvalumab adjuvant treatment for muscle-invasive bladder cancer
Neoadjuvant treatment of durvalumab in combination with gemcitabine-cisplatin and adjuvant treatment of durvalumab alone are currently in clinical development for patients with muscle-invasive bladder cancer (MIBC). Bladder cancer is where a growth of abnormal tissue, known as a tumour, develops in the bladder lining. When the cancerous cells spread beyond the lining, into the surrounding […]
DownloadNiraparib with abiraterone acetate and prednisone for metastatic castration resistant prostate cancer
Niraparib with abiraterone acetate and prednisone (AAP) is in clinical development for patients with prostate cancer which has spread from its original site (metastatic) and is untreatable via testosterone suppression therapy (castration resistant). Prostate cancer is a cancer of the prostate gland (a small organ in a man’s pelvis) and is the most common cancer […]
DownloadLetermovir for preventing cytomegalovirus disease in kidney transplant patients
Letermovir is in clinical development for adult patients who have received a kidney transplant and are at risk of developing cytomegalovirus disease (CMV). CMV is normally a mild infection that causes flu-like symptoms but can be life-threatening in certain groups. Once infected with CMV, the virus stays in the body throughout a person’s life with […]
DownloadEfanesoctocog alfa for treating and preventing bleeding in people with haemophilia A who have been previously treated
Efanesoctocog alfa is currently in clinical development for the treatment and prevention (prophylaxis) of bleeding episodes in patients with haemophilia A. Haemophilia A is a genetic bleeding disorder caused by a deficiency or absence of a blood clotting factor, called factor VIII (eight). This causes poor blood clotting, which results in difficulty in stopping the […]
DownloadIvosidenib for previously treated advanced cholangiocarcinoma
Cholangiocarcinoma is a rare type of cancer that affects the bile ducts. Different subtypes of cholangiocarcinoma are classified by the location at which they develop in the biliary tract. Genetic changes (mutations) to the metabolic enzyme isocitrate dehydrogenase 1 (IDH1) plays a central role in development of cholangiocarcinoma by contributing to the growth of abnormal […]
DownloadEnzalutamide for treating non-metastatic prostate cancer after radical prostatectomy and/or radiotherapy
Enzalutamide is currently in clinical development for the treatment of high-risk non-metastatic prostate cancer (cancer that has not spread beyond the prostate) that has been previously treated with a radical prostatectomy (surgery to remove the prostate gland) and/or radiotherapy. Prostate cancer develops in the prostate gland and is the most common cancer in men in […]
DownloadNivolumab with ipilimumab adjuvant therapy for renal cell carcinoma
Nivolumab in combination with ipilimumab is in clinical development as adjuvant therapy for adult patients with localised renal cell carcinoma (RCC) who underwent partial or entire removal of a kidney. RCC (the most common type of kidney cancer in adults) is a disease that affects the lining of tiny tubes within the kidney which filter […]
DownloadMirabegron for neurogenic detrusor overactivity in people aged 3 to 17 years
Mirabegron is currently in clinical development for treatment of neurogenic detrusor overactivity(NDO) in children and adolescents aged 3 to 17 years old on clean intermittent catheterisation(CIC). NDO is a bladder dysfunction and can cause urinary symptoms such as frequency, urgencyand urinary incontinence. Other symptoms of NDO include: pelvic pain, painful urination,incontinence, increased spasticity, autonomic dysreflexia, […]
DownloadTislelizumab with etoposide and carboplatin or cisplatin for treating small-cell lung cancer
Tislelizumab in combination with chemotherapy is currently in clinical development for the first-line treatment of extensive stage small-cell lung cancer (SCLC). Extensive stage SCLC is whencancer cells form in the tissues of the lung and spread beyond the lung to other places in the body.Symptoms include chest discomfort or pain, a cough that does not […]
DownloadPembrolizumab with stereotactic body radiotherapy for unresected stage I or II non-small cell lung cancer
Pembrolizumab with stereotactic body radiotherapy (SBRT) is currently in development for patients withunresected stage I or II (stage IIB N0, M0) non-small cell lung cancer (NSCLC). NSCLC is the most commontype of lung cancer. Stage I NSCLC is small; contained inside the lung and has not spread to lymph nodes;and stage IIB is up to […]
DownloadTislelizumab with chemotherapy for previously untreated unresectable or metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma
Tislelizumab in combination with chemotherapy is being developed for the first-line treatment oflocally advanced, unresectable or metastatic gastric cancer (GC) or gastroesophageal junction(GEJ) adenocarcinoma. GC is a cancer that starts in the stomach. GEJ adenocarcinoma is cancerthat starts at the gastro-oesophageal junction, where the food pipe (oesophagus) joins thestomach. Risk factors of GC and GEJ […]
DownloadDersimelagon for previously untreated erythropoietic protoporphyria and X-linked protoporphyria
Dersimelagon is being developed for the treatment of erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP). EPP and XLP are rare diseases that cause intolerance to light. Inpatients with EPP or XLP, exposure to light can lead to symptoms such as pain and swelling of theskin, which prevent patients from being able to spend time outdoors […]
DownloadAcalabrutinib with bendamustine and rituximab for treating previously untreated mantle cell lymphoma
Acalabrutinib in combination with bendamustine and rituximab is in clinical development for thefirst line treatment of mantle cell lymphoma (MCL). MCL is a rare and aggressive form of nonHodgkin lymphoma. It affects the B-cells (a type of white blood cells) and develops in the lymphnodes. The abnormal B-cells start to collect in the lymph nodes […]
DownloadRibociclib with endocrine therapy for HR+/HER2- early breast cancer – adjuvant treatment
Ribociclib with endocrine therapy (ET) is currently in clinical development for patients with earlybreast cancer with hormone receptor positive (HR+)/human epidermal receptor 2 negative(HER2-) subtype. Early breast cancer is where the disease is limited to the breast region and hasnot spread to other parts of the body. Symptoms include swelling of breast regions, breast ornipple […]
DownloadBardoxolone Methyl for the treatment of chronic kidney disease (CKD) caused by Alport Syndrome
Bardoxolone methyl is in clinical development for the treatment of patients aged 12 years andolder with Alport syndrome. Alport syndrome is a genetic condition characterized by kidneydisease, hearing loss, and eye abnormalities. It is caused by a defect (mutation) in a gene for aprotein in the connective tissue, called collagen. There are currently no licensed […]
DownloadAtezolizumab with chemotherapy for treating recurrent triple-negative breast cancer
Atezolizumab with chemotherapy is currently in clinical development for the treatment of earlyrelapsing, recurrent triple-negative breast cancer (TNBC). TNBC is an uncommon form kind ofbreast cancer where the tumour cells do not have any of the receptors that are commonly foundin breast cancer. TNBC is often more aggressive and harder to treat compared to other […]
DownloadSacubitril-valsartan for previously untreated chronic heart failure with reduced ejection fraction in children
Sacubitril-valsartan is currently in clinical development for the treatment of paediatric chronicheart failure (HF) with reduced ejection fraction. HF is a clinical syndrome of symptoms and signsthat suggest the efficiency of the heart to pump blood around the body is impaired. The classicalpresenting symptoms of HF in young children are feeding difficulties, growth failure, irritability,and […]
DownloadMasitinib with Riluzole for amyotrophic lateral sclerosis
Masitinib in combination with riluzole is in clinical development for the treatment of patients withthe amyotrophic lateral sclerosis (ALS), form of motor neurone disease (MND). ALS is aprogressive disease of the nervous system, where nerve cells in the brain and spinal cord thatcontrol voluntary movement gradually deteriorate, causing loss of muscle function and paralysis.ALS is […]
Download
